Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.69 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915694 | 1.00 | CCR5 (0.69) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL14168737 | 0.94 | CCR5 (0.62) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL12611680 | 0.92 | CCR5 (0.58) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL13714539 | 0.90 | CCR5 (0.65) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL15169901 | 0.89 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL174295 | 0.89 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL174296 | 0.89 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL14191197 | 0.87 | CCR5 (0.68) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL13714452 | 0.87 | CCR5 (0.68) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL14168713 | 0.87 | CCR5 (0.53) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3521274-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-01 | — | — | US | disclosed |
| WO-2018059279-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | 中国科学院上海药物研究所 | 2018-04-05 | — | — | WO | disclosed |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7576097-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576097-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | PRMT3, GRIN3A, RAMP3 | CCR5 14/4885KCNH2 2108/4885CYP3A4 255/4885 |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | PRMT3, GRIN3A, RAMP3 | CCR5 14/4885KCNH2 2108/4885CYP3A4 255/4885 |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | CCR5, CCR8, CCL5 | CCR5 1/4885KCNH2 3936/4885CYP3A4 468/4885 |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | ADRB3, ADRB2, ADRA2C | CCR5 407/4885KCNH2 1335/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.